The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
- Autori: Agostinelli, C.; Gallamini, A.; Stracqualursi, L.; Agati, P.; Tripodo, C.; Fuligni, F.; Sista, M.; Fanti, S.; Biggi, A.; Vitolo, U.; Rigacci, L.; Merli, F.; Patti, C.; Romano, A.; Levis, A.; Trentin, L.; Stelitano, C.; Borra, A.; Piccaluga, P.; Hamilton-Dutoit, S.; Kamper, P.; Zaucha, J.; Małkowski, B.; Kulikowski, W.; Tajer, J.; Subocz, E.; Rybka, J.; Steidl, C.; Broccoli, A.; Argnani, L.; Gascoyne, R.; D'Amore, F.; Zinzani, P.; Pileri, S.
- Anno di pubblicazione: 2016
- Tipologia: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/203281
Abstract
Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.